Search - tctmd.com

Displaying 761 - 780 of 815

Sort: Relevancy | Date

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Michael O'Riordan

June 09, 2016

News Daily News

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Michael O'Riordan

March 08, 2016

News Daily News

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Michael O'Riordan

March 02, 2016

News Daily News

Robert Califf’s FDA Nomination Gets Unanimous Yes from US Senate Committee

Shelley Wood

January 11, 2016

News Daily News

Medicare Part D Has Scant Effect on Outcomes for Acute MI Patients

Yael L. Maxwell

November 04, 2015

News Daily News

Battle Scars: Combat Injury Linked With Cardiovascular Risk

Caitlin E. Cox

November 04, 2015

News Daily News

La Puerta se Cierra para las Dietas Bajas en Grasas en lo que al Manejo del Peso a Largo Plazo se refiere

Todd Neale

November 01, 2015

News Daily News

Door Closing on Low-fat Diets for Long-term Weight Management

Todd Neale

November 01, 2015

News Daily News

NEJM Endorses Robert Califf for FDA Commissioner

L.A. McKeown

October 30, 2015

News Daily News

NEJM Apoya a Robert Califf como Comisionado de la FDA

L.A. McKeown

October 30, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

Presentation

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Presenter: BM. Everett BM

August 14, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Yael L. Maxwell

August 12, 2015

Presentation

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial

Presenter: Vera Bittner

August 11, 2015

Advertisement

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Detection and Treatment of Severe FH Depends on LDL Levels, Not Genes, Says Expert Panel

Controversial LIGHT Trial Now Published but Fails to Illuminate CV Risks of Contrave

Optimal Risk Factor Control Translates Into Less Expenditure on Healthcare, Use of Resources

Robert Califf’s FDA Nomination Gets Unanimous Yes from US Senate Committee

Medicare Part D Has Scant Effect on Outcomes for Acute MI Patients

Battle Scars: Combat Injury Linked With Cardiovascular Risk

La Puerta se Cierra para las Dietas Bajas en Grasas en lo que al Manejo del Peso a Largo Plazo se refiere

Door Closing on Low-fat Diets for Long-term Weight Management

NEJM Endorses Robert Califf for FDA Commissioner

NEJM Apoya a Robert Califf como Comisionado de la FDA

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content